1.21 USD
+0.020.00%
盘后 1.22 +0.41%
2026-08-03
市值
$45.55M
市盈率
—
EPS
-2.30
股息率
—
52 周区间
1.13 – 3.95
成交量
103.35K
Beta
0.70
目标价
7.67
52W 低 1.1352W 高 3.95
价格走势
公司简介
Metagenomi Therapeutics, Inc. an in vivo genome editing company, develops curative genetic medicines in the United States. The company’s lead development program, MGX-001, is designed to provide curative, life-long protection from bleeding events and joint damage in adults and children with hemophilia. It has a collaboration agreement with Ionis Pharmaceuticals, Inc. for apolipoprotein C-III for the treatment of hyper triglyceridemia, transthyretin (TTR) for transthyretin amyloidosis, angiotensinogen (AGT) for refractory hypertension, and other...